Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
Background Multiple PD-L1 immunohistochemistry (IHC) assays, including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1 IHC assays, have been approved by the Food and Drug Administration as a companion diagnostic (CDx) for various antiprogrammed death-1 and antiprogrammed death ligand 1 (PD-L1) based c...
Saved in:
Main Authors: | Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-10-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/10/e005573.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
by: Vivek Subbiah, et al.
Published: (2025-02-01) -
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
by: Alfred Zippelius, et al.
Published: (2022-11-01) -
Gastrointestinal stromal tumors
by: A. P. Seryakov
Published: (2010-08-01) -
Prognostic value of tumor‐infiltrating lymphocytes and PD‐L1 expression in esophageal squamous cell carcinoma
by: Jie Hu, et al.
Published: (2024-09-01) -
Tumor microbiome: roles in tumor initiation, progression, and therapy
by: Shengxin Zhang, et al.
Published: (2025-02-01)